Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MarsLight-11: TAK-928 vs docetaxel in immunotherapy-resistant squamous non-small cell lung cancer
jRCT2031260152Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of IBI363 in Pulmonary squamous cell carcinoma (2 arms), sponsored by Takeda. Primary endpoints: Global Part: Confirmed Objective Response Rate (cORR) by BICR per RECIST v1.1, Global Part: Overall Survival (OS) and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
IBI363
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2031260152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260152.